

Alessia Bari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6959273/publications.pdf>

Version: 2024-02-01

68
papers

1,222
citations

361413

20
h-index

377865

34
g-index

69
all docs

69
docs citations

69
times ranked

2036
citing authors

#	ARTICLE	IF	CITATIONS
1	Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review by the Fondazione Italiana Linfomi. <i>Cancers</i> , 2022, 14, 519.	3.7	2
2	Management of lymphoma survivor patients in Italy: an evaluation by Fondazione Italiana Linfomi. <i>Tumori</i> , 2021, 107, 91-94.	1.1	11
3	Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 766-770.	0.9	5
4	The Impact of Healthy Lifestyles on Late Sequelae in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors. A Systematic Review by the Fondazione Italiana Linfomi. <i>Cancers</i> , 2021, 13, 3135.	3.7	9
5	Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma. <i>Cancers</i> , 2021, 13, 4978.	3.7	6
6	Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi. <i>Journal of Geriatric Oncology</i> , 2020, 11, 37-40.	1.0	14
7	The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments. <i>Annals of Hematology</i> , 2020, 99, 277-282.	1.8	11
8	Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma. <i>Hematological Oncology</i> , 2020, 38, 439-445.	1.7	4
9	The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis. <i>Leukemia and Lymphoma</i> , 2019, 60, 1958-1964.	1.3	4
10	Clusterin enhances AKT-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit. <i>Journal of Cellular Physiology</i> , 2019, 234, 11188-11199.	4.1	19
11	Absolute monocyte count at diagnosis could improve the prognostic role of early ¹⁸F-FDG PET in classical Hodgkin lymphoma patients. <i>British Journal of Haematology</i> , 2018, 180, 600-602.	2.5	2
12	Prognostication of Diffuse Large B-Cell Lymphoma By Lympho2Cx Assay and BCL2 and MYC Expression: Application in a Real Life Context of 154 Patients. <i>Blood</i> , 2018, 132, 5308-5308.	1.4	0
13	A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up. <i>Acta Haematologica</i> , 2017, 137, 7-14.	1.4	4
14	Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. <i>Leukemia and Lymphoma</i> , 2017, 58, 552-559.	1.3	9
15	Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients. <i>Hematological Oncology</i> , 2017, 35, 561-566.	1.7	36
16	Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1615-1621.	3.4	27
17	A pooled data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL): Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in non-Hodgkin lymphoma (NHL). <i>Annals of Oncology</i> , 2016, 27, vi316.	1.2	1
18	Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2016, 101, e196-e199.	3.5	15

#	ARTICLE	IF	CITATIONS
19	The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines. <i>Cancer Biology and Therapy</i> , 2016, 17, 1094-1106.	3.4	25
20	Reduced intensity <sc>VEPEMB</sc> regimen compared with standard <sc>ABVD</sc> in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (<sc>FIL</sc>). <i>British Journal of Haematology</i> , 2016, 172, 879-888.	2.5	29
21	The Absolute Monocyte Count at Diagnosis Could Improve the Prognostic Role of the End of Treatment 18-FDG-PET in Diffuse Large B Cell Lymphoma (DLBCL) Patients. <i>Blood</i> , 2016, 128, 5406-5406.	1.4	0
22	The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines. <i>Hematological Oncology</i> , 2015, 33, 166-175.	1.7	15
23	Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study. <i>Journal of Breast Cancer</i> , 2015, 18, 378.	1.9	25
24	Activity of BKM120 and BEZ235 against Lymphoma Cells. <i>BioMed Research International</i> , 2015, 2015, 1-12.	1.9	13
25	Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients. <i>Mayo Clinic Proceedings</i> , 2015, 90, 756-764.	3.0	39
26	Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the <sc>FOLL</sc>05 trial of the Fondazione Italiana Linfomi. <i>British Journal of Haematology</i> , 2015, 169, 544-551.	2.5	20
27	Khorana Score and Histotype Predict the Incidence of Early Venous Thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL): a Pooled Data Analysis of Twelve Clinical Trials of Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2015, 126, 3934-3934.	1.4	1
28	Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery. <i>Blood</i> , 2015, 126, 4851-4851.	1.4	0
29	Neutrophil - Lymphocyte Ratio (NLR) at Diagnosis Is an Independent Prognostic Factor in Patients with Nodular Sclerosis Hodgkin Lymphoma: Results of a Large Multicenter Study Involving 990 Patients. <i>Blood</i> , 2015, 126, 3862-3862.	1.4	0
30	Neutrophil to Lymphocyte Ratio at Diagnosis Is an Independent Prognostic Factor in Diffuse Large B-Cell Lymphoma: Results of a Large Multicenter Study Involving 931 Patients. <i>Blood</i> , 2015, 126, 1465-1465.	1.4	0
31	The potential of pralatrexate as a treatment of peripheral T-cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 711-718.	4.1	3
32	Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to <sc>M</sc>urphy <i>et al</i>. <i>British Journal of Haematology</i> , 2014, 165, 892-892.	2.5	1
33	Defining the best cutoff value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy. <i>British Journal of Haematology</i> , 2014, 167, 133-136.	2.5	6
34	Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era. <i>Haematologica</i> , 2014, 99, 125-130.	3.5	77
35	Long-Term Follow-up Analysis of HD2000 Trial Comparing ABVD Versus BEACOPP Versus Copp/EBV/CAD in Patients with Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study from the Fondazione Italiana Linfomi. <i>Blood</i> , 2014, 124, 499-499.	1.4	1
36	Prognostic Role of Serum Albumin Level in DLBCL before and during the Rituximab Era. Retrospective GISL Study over 738 Cases. <i>Blood</i> , 2014, 124, 5411-5411.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Prognostic Score Based on Clinical and Biochemical Surrogates of Disease Status in DLBCL Treated with Chemo-Immunotherapy. <i>Blood</i> , 2014, 124, 3027-3027.	1.4	0
38	Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas. <i>Leukemia Research</i> , 2013, 37, 619-623.	0.8	24
39	Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. <i>British Journal of Haematology</i> , 2013, 163, 40-46.	2.5	80
40	Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. <i>European Journal of Haematology</i> , 2013, 90, 345-348.	2.2	37
41	Rituximab Maintenance Compared With Observation After Brief First-Line R-FND Chemoimmunotherapy With Rituximab Consolidation in Patients Age Older Than 60 Years With Advanced Follicular Lymphoma: A Phase III Randomized Study by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013, 31, 3351-3359.	1.6	54
42	Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. <i>Blood</i> , 2013, 122, 3759-3766.	1.4	82
43	Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 4383-4383.	1.4	1
44	Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines. <i>Annals of Hematology</i> , 2012, 91, 1613-1622.	1.8	8
45	In Vitro Combination of Bortezomib with Enzastaurin or Lenalidomide Enhances the Cytotoxicity in B-Cell Lymphoma Cell Lines.. <i>Blood</i> , 2012, 120, 2754-2754.	1.4	1
46	Monocytosis Has Adverse Prognostic Significance and Impacts Survival in Patients with T-Cell Lymphomas.. <i>Blood</i> , 2012, 120, 2647-2647.	1.4	0
47	Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1029-1031.	4.1	7
48	Genomic profiling of enzastaurin-treated B cell lymphoma RL cells. <i>Hematological Oncology</i> , 2011, 29, 154-156.	1.7	4
49	Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis. <i>Annals of Oncology</i> , 2011, 22, 1845-1858.	1.2	76
50	Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1867-1872.	1.3	43
51	THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011065.	1.3	15
52	Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL). <i>Blood</i> , 2011, 118, 777-777.	1.4	4
53	Relative Survival and Incidence Based Mortality of Diffuse Large B-Cell Lymphoma (DLBCL) in Rituximab Era: Population Based Study From Modena Cancer Registry (MCR). <i>Blood</i> , 2011, 118, 5185-5185.	1.4	0
54	Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. <i>Annals of Oncology</i> , 2010, 21, 1486-1491.	1.2	79

#	ARTICLE	IF	CITATIONS
55	Phase II Study of Velcade® Plus Mabthera® In Relapsed Follicular Lymphomas. <i>Blood</i> , 2010, 116, 1801-1801.	1.4	1
56	Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma. <i>Cancer</i> , 2009, 115, 1906-1913.	4.1	6
57	Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies.. <i>Blood</i> , 2009, 114, 1918-1918.	1.4	0
58	Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. <i>Haematologica</i> , 2008, 93, 398-404.	3.5	92
59	Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study. <i>Haematologica</i> , 2008, 93, 1335-1342.	3.5	35
60	Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma?. <i>Annals of Oncology</i> , 2007, 18, 351-356.	1.2	39
61	Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. <i>Hematological Oncology</i> , 2007, 25, 189-197.	1.7	49
62	Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. <i>Cancer</i> , 2007, 109, 2077-2082.	4.1	50
63	Incidence and Outcome of Myelodysplastic Syndromes in Province of Modena.. <i>Blood</i> , 2007, 110, 4610-4610.	1.4	1
64	Incidence and Outcome of Chronic Myeloproliferative Disorders: A Population-Based Study from a Cancer Registry in Northern Italy.. <i>Blood</i> , 2007, 110, 4650-4650.	1.4	0
65	Secondary Malignancies after Treatment of Aggressive Non-Hodgkin Lymphoma: A GISL Cohort Study on 1259 Patients.. <i>Blood</i> , 2007, 110, 522-522.	1.4	0
66	Incidence, Clinical Characteristics and Survival of Malignant Lymphomas in the Province of Modena (Italy); a Population-Based Study.. <i>Blood</i> , 2006, 108, 4628-4628.	1.4	0
67	A concise review of lenalidomide therapy for follicular lymphoma. <i>Expert Opinion on Orphan Drugs</i> , 0, , 1-7.	0.8	0
68	Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial. <i>Blood Advances</i> , 0, , .	5.2	0